were selected to be assessed against this small panel for inhibitory activity at a single dose of 10 µM. We found that analogs 20 and 38 did display inhibition of insulin receptor kinase (IRK) at 57% and 64% inhibition, respectively (Table ). Conversely, analog 39 only exhibited 4% inhibition against IRK. For the remaining kinases, analog 20 displayed 28% inhibition versus vascular endothelial growth factor receptor-2 (VEGFR2) but did not exhibit any inhibition toward leukocyte C-terminal Src kinase (LCK) or Rho-associated coiled-coil containing kinase (ROCK1).